This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Web of Science (2) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Herrmann, N. Articles by Khan, L. R. Search for Related Content PubMed PubMed Citation Articles by Herrmann, N. Articles by Khan, L. R. Social Bookmarking                         What's this?

Noradrenergic Activity is Associated with Response to Pindolol in Aggressive Alzheimer’s Disease Patients

Department of Psychiatry, Sunnybrook and Women’s College Health Sciences Centre and University of Toronto, Toronto, Ontario, Canada., nathan.herrmann{at}sw.ca

Krista L. Lanctôt

Department of Psychiatry, Sunnybrook and Women’s College Health Sciences Centre and Departments of Psychiatry and Pharmacology, University of Toronto, Toronto, Ontario, Canada.

Goran Eryavec

Department of Psychiatry, North York General Hospital and University of Toronto, Toronto, Ontario, Canada.

Lyla R. Khan

Department of Psychiatry, Sunnybrook and Women’s College Health Sciences Centre, Toronto, Ontario, Canada.

Loss of noradrenergic (NE) neurones in the locus ceruleus and compensatory changes in NE activity have been described in Alzheimer’s disease (AD), but have never been linked to treatment. The hypothesis of this study was that central NE responsivity would predict aggression response to treatment with a NE medication, pindolol. Fifteen institutionalized AD subjects [Mini-Mental State Examination (MMSE), mean 3.3 ± 4.6] with significant behavioural disturbances (Neuropsychiatric Inventory Score, mean 30.6 ± 14.6) were studied. Growth hormone (GH) response to clonidine challenge (5 µg/kg) was used as a measure of central NE responsivity. Subjects were then randomized to 7 weeks of treatment with pindolol, maximum dose 20 mg b.i.d., or an identical placebo capsule in a cross-over design. The primary outcome measure was change on the retrospective Overt Aggression Scale (r-OAS). Five of 11 completers (45%) had decreased total r-OAS scores. There was significant improvement noted on the r-OAS verbal aggression subscale (paired t = -2.5, p = 0.03) compared to placebo, but not r-OAS total. Higher baseline aggression, higher MMSE and lower GH response predicted improvement in aggression, accounting for 82% of the variance (r = 0.91, F = 10.5, p = 0.006). Changes in NE responsivity, as reflected by a blunted GH response to clonidine challenge and more severe aggression, were associated with better response to the NE agent pindolol. Individual patient characteristics, including underlying neurotransmitter changes, may be useful for predicting response to therapy.

Key Words: aggression • Alzheimer’s disease • behavioural and psychological symptoms of dementia • neurochemical pathology • norepinephrine

Journal of Psychopharmacology, Vol. 18, No. 2, 215-220 (2004)
DOI: 10.1177/0269881104042625


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?